Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Piramal Acquisition Is $3.72 Billion Push In Emerging Markets With Established Products

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Abbott is all set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare, ending months of speculation on which multinational would secure India's fourth-largest pharma compan
Advertisement

Related Content

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
Abbott, GSK, And Heinz Vying Again For Indian Wockhardt's Nutrition Brands
Abbott's Top India Product Phensedyl Nosedives As India Faces Severe Codeine Shortage
As Korea Pharmas Look To U.S., U.S. VC Looks To Korea
Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures
Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures
MNCs Return To India With Big Bang; Some Call It Their Waterloo, Others Say Time To Grow Strong
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
Advertisement
UsernamePublicRestriction

Register

SC074867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel